Vir Biotechnology, Inc.
$11.09
▲
0.44%
2026-04-21 10:07:01
www.vir.bio
NMS: VIR
Explore Vir Biotechnology, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.72 B
Current Price
$11.09
52W High / Low
$10.94 / $4.16
Stock P/E
—
Book Value
$5.49
Dividend Yield
—
ROCE
-52.69%
ROE
-45.73%
Face Value
—
EPS
$-3.16
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
367
Beta
1.66
Debt / Equity
12.79
Current Ratio
5.54
Quick Ratio
5.54
Forward P/E
-4.22
Price / Sales
22.15
Enterprise Value
$956.25 M
EV / EBITDA
-2.1
EV / Revenue
13.95
Rating
None
Target Price
$20.78
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Kodiak Sciences Inc. | $46.44 | — | $2.87 B | — | -76.6% | -1.49% | $47.41 / $2.34 | $2.55 |
| 2. | NovaBay Pharmaceuticals Inc | $1.4 | — | $51.92 M | 0% | -96.1% | 190.01% | $99.75 / $1.11 | $-0.92 |
| 3. | ImageneBio, Inc. | $6 | — | $65.99 M | — | -34.18% | -68.91% | $18 / $3.94 | $11.91 |
| 4. | Karyopharm Therapeutics Inc. | $8.94 | — | $193.06 M | — | -554.58% | 81.86% | $10.99 / $3.65 | $-16 |
| 5. | Immunic, Inc. | $0.95 | — | $124.59 M | — | 1572.16% | -16.53% | $1.51 / $0.51 | $-0.06 |
| 6. | Moleculin Biotech, Inc. | $2.56 | — | $13.66 M | — | -164.37% | -2.56% | $28.61 / $1.79 | $4.69 |
| 7. | Ginkgo Bioworks Holdings, Inc. | $7.98 | — | $492.71 M | — | -29.68% | -51.08% | $17.58 / $5.37 | $8.74 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 63.76 M | -0.07 M | 1.03 M | 1.79 M | 11.28 M | — |
| Operating Profit | -47.92 M | -173.44 M | -118.59 M | -139.56 M | -121.09 M | — |
| Net Profit | -42.92 M | -163.14 M | -110.96 M | -120.97 M | -104.59 M | — |
| EPS in Rs | -0.27 | -1.02 | -0.69 | -0.76 | -0.65 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 66.52 M | 63.71 M | 39.49 M | 1.58 B |
| Operating Profit | -479.51 M | -552.17 M | -670.75 M | 833.07 M |
| Net Profit | -437.99 M | -521.96 M | -615.06 M | 515.84 M |
| EPS in Rs | -2.74 | -3.27 | -3.85 | 3.23 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1 B | 1.4 B | 1.92 B | 2.8 B |
| Total Liabilities | 237.55 M | 248.43 M | 328.82 M | 724.12 M |
| Equity | 765.28 M | 1.15 B | 1.59 B | 2.08 B |
| Current Assets | 514.08 M | 1.04 B | 1.59 B | 2.52 B |
| Current Liabilities | 92.81 M | 119.66 M | 175.41 M | 511.03 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -391.78 M | -446.35 M | -778.78 M | 1.66 B |
| Investing CF | 310.37 M | 499.37 M | 164.63 M | -1.19 B |
| Financing CF | 3.79 M | 4.39 M | 7.48 M | 34.76 M |
| Free CF | -396.61 M | -453.65 M | -800.36 M | 1.6 B |
| Capex | -4.83 M | -7.3 M | -21.57 M | -68.01 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 4.41% | 61.32% | -97.5% | — |
| Earnings Growth % | 16.09% | 15.14% | -219.24% | — |
| Profit Margin % | -658.43% | -819.25% | -1557.35% | 32.64% |
| Operating Margin % | -720.85% | -866.67% | -1698.35% | 52.71% |
| Gross Margin % | 99.96% | 98.67% | 93% | 90.74% |
| EBITDA Margin % | -703.29% | -843.81% | -1649.1% | 53.14% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.